Moreover, downregulation of cPLA2 by specific siRNA pool led to diminished apoptotic response of A549 cells to treatment with cisplatin and oxaliplatin (assessed by decreased levels of processed caspase-3 and –9), indicating that cPLA2 activity is involved in the regulation of NSCLC cells’ chemosensitivity (Fig. 5C). The gene discussed is PLA2G4A; the disease is non-small cell lung carcinoma.